Showing 1 - 3 results of 3 for search 'Qiuling Zhao', query time: 0.01s Refine Results
  1. 1
    Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States

    Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States... by Qiuling Zhao, Yimin He, Zilin Nian, Yongjian Huang, Ruyi Huang, Lijun Lai, Lin Yang

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Enhanced Optoelectronic Response of TiO<sub>2</sub> Photodetector Sensitized via CuInSe<sub>2</sub> Quantum Dots

    Enhanced Optoelectronic Response of TiO<sub>2</sub> Photodetector Sensitized via CuInSe<sub>2</sub> Quantum Dots by Yanxu Zhang, Kexin Yu, Jin Zhao, Shuaiqi Xu, Mengqi Lv, Qiuling Zhao, Xue Du, Maorong Wang, Xia Wang

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model

    Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-eff... by Lin Yang, Ting Chen, Qiuling Zhao, Liangliang Dong, Wanfu Zhong, Wenbin Liu, Xiuliang Qiu, Ruyi Huang, Shengqiang Huang, Ruixiang Xie

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: